Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed ovarian epithelial, primary serous type peritoneal, or
fallopian tube carcinoma

- Patients with ovarian cancer of the clear cell histology are eligible.
Histologic confirmation is preferably by biopsy or limited excision prior to
neo‐adjuvant treatment. If the diagnosis prior to neo-adjuvant chemotherapy is
based on cytology, histologic confirmation is required prior to randomization.
Histologic confirmation can be obtained at the time of debulking surgery by
intra-operative frozen section, thus permitting intra-operative randomization,
or by final pathologic review of the resected specimen if randomization is to be
performed following debulking surgery.

- Initial FIGO stage IIB-III disease

- Stage IV disease allowed provided the only criterion for stage IV disease
is the presence of a pleural effusion confirmed to be associated with
positive cytology for ovarian cancer

- Completed ≥ 3 but no more than 4 courses of platinum-based neoadjuvant chemotherapy
prior to the first debulking surgery

- Meets the following criteria for surgical treatment prior to randomization:

- Initial Diagnosis: No debulking surgery was attempted or completed.

- The patient's first cytoreductive (debulking) surgery must be after neoadjuvant
chemotherapy (Delayed Primary Debulking). The delayed primary debulking surgery
must be completed no more than 4 weeks after commencing administering of the
last cycle of neoadjuvant chemotherapy and must be completed no more than 6
weeks prior to randomization.

- Surgery will include total abdominal hysterectomy, bilateral
salpingo-oophorectomy, omentectomy and any additional procedures required to
achieve maximal cytoreduction with residual disease of 1 cm or less as assessed
by the surgeon at the end of surgery.

- Delayed primary debulking surgery must be completed no more than 4 weeks
after the last course of neoadjuvant chemotherapy and must be completed no
more than 6 weeks prior to randomization

- Surgery will include total abdominal hysterectomy, bilateral
salpingo-oophorectomy, omentectomy, and any additional procedures required to
achieve maximal cytoreduction with residual disease of ≤ 1 cm as assessed by the
surgeon at the end of surgery

- No borderline ovarian tumors (i.e., tumors of low malignant potential) alone

- No mucinous tumor

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Life expectancy ≥ 12 weeks

- Granulocyte count ≥ 1.5 x 10^9/L

- Platelet count ≥ 100 x 10^9/L

- Serum creatinine ≤ upper limit of normal (ULN) OR > ULN to ≤ 1.25 ULN provided
measured creatinine clearance is > 60 mL/min

- Serum bilirubin normal

- AST/ALT ≤ 2.5 times ULN

- Fertile patients must use effective contraception

- Able (i.e., sufficiently fluent) and willing to complete the quality of life
questionnaires

- Accessible for treatment and follow-up

- No history of other malignancy, except adequately treated nonmelanoma skin cancer,
curatively treated carcinoma in situ of the cervix, or other solid tumors curatively
treated with no evidence of disease for ≥ 5 years

- No uncontrolled atrial or ventricular arrhythmias including second or third degree
heart block unless managed with implanted pacemaker

- Patients with a history of first degree heart block are eligible

- No documented myocardial infarction within the past 6 months preceding randomization
(pretreatment ECG evidence only of infarct will not exclude patients)

- No diagnosis of bowel obstruction

- No serious illness or medical condition which would not permit the patient to be
managed according to protocol including, but not limited to, any of the following:

- Prior allergic reactions to drugs containing cremophor or to compounds
chemically related to cisplatin, paclitaxel, or carboplatin

- Symptomatic congestive heart failure within the past 6 months or other
conditions which would lead to a contraindication of a high-volume saline
diuresis

- History of significant neurologic or psychiatric disorder which would impair the
ability to obtain consent

- Active uncontrolled infection

- Persistent peripheral neuropathy or hearing loss ≥ grade 2 resulting from prior
therapy

- Extensive intraperitoneal adhesion intra- or post-operatively which would impede
intraperitoneal treatment delivery

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior therapy for ovarian cancer, except for neoadjuvant platinum-based
chemotherapy and surgery

- No concurrent intraperitoneal adhesion barriers

- No other concurrent anticancer treatment, including cytotoxic agents, biological
response modifiers, immunotherapy, anticancer hormone therapy, or investigational
drug therapy

- No other concurrent experimental drugs or anticancer therapy